NeoGenomics, Inc. (NEO)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NeoGenomics, Inc. (NEO) trades at $7.55 with AI Score 49/100 (Weak). NeoGenomics, Inc. is a cancer-focused testing laboratory network operating in the United States, Europe, and Asia. Market cap: 197M, Sector: Healthcare.
Last analyzed: Mar 15, 2026NeoGenomics, Inc. (NEO) Healthcare & Pipeline Overview
NeoGenomics, Inc. provides cancer-focused testing services, including cytogenetics and molecular analysis, to hospitals, pharmaceutical firms, and researchers across the United States, Europe, and Asia. With a focus on oncology programs, NeoGenomics operates through Clinical Services and Pharma Services segments, offering a broad range of diagnostic and testing solutions.
Investment Thesis
NeoGenomics, Inc. presents a compelling investment thesis based on its established position in the cancer diagnostics market and its dual revenue streams from clinical and pharmaceutical services. Despite a negative P/E ratio of -1.88 and a negative profit margin of -14.9%, the company's gross margin of 42.2% indicates underlying profitability potential. Growth catalysts include expanding partnerships with pharmaceutical companies and increasing demand for advanced cancer diagnostics. Key value drivers include the company's comprehensive testing portfolio and its strategic geographic presence. Potential risks include market competition from companies like ACRS, ARCT, HUMA, MDXH, and QTRX, as well as regulatory changes in the healthcare industry. Investors should monitor the company's ability to improve profitability and capitalize on growth opportunities in the oncology market.
Based on FMP financials and quantitative analysis
Key Highlights
- NeoGenomics operates through Clinical Services and Pharma Services segments, providing diverse revenue streams.
- The company's gross margin stands at 42.2%, indicating potential for profitability improvements.
- NeoGenomics has a market capitalization of $0.20 billion, reflecting its current market valuation.
- The company serves a broad range of clients, including hospitals, pharmaceutical firms, and researchers.
- NeoGenomics has a strategic alliance with Inivata Limited, enhancing its market reach and capabilities.
Competitors & Peers
Strengths
- Comprehensive range of cancer-focused testing services.
- Established network of laboratories in the United States, Europe, and Asia.
- Dual revenue streams from clinical and pharmaceutical services.
- Strategic alliance with Inivata Limited.
Weaknesses
- Negative P/E ratio and profit margin.
- High beta of 1.64, indicating higher volatility compared to the market.
- Reliance on third-party suppliers for reagents and equipment.
- Exposure to regulatory changes in the healthcare industry.
Catalysts
- Expansion of Pharma Services segment to capitalize on oncology drug development.
- Strategic partnerships with hospitals and research institutions to enhance market reach.
- Advancements in molecular testing and personalized medicine to improve diagnostic accuracy.
- Geographic expansion into international markets to drive growth.
- Integration of data analytics and artificial intelligence (AI) into testing services.
Risks
- Intense competition from other diagnostic testing companies.
- Reimbursement rate reductions from healthcare payers.
- Risk of intellectual property infringement.
- Economic downturn affecting healthcare spending.
- Regulatory changes in the healthcare industry.
Growth Opportunities
- Expanding Pharma Services: NeoGenomics can capitalize on the growing demand for oncology drug development support by expanding its Pharma Services segment. This involves providing comprehensive testing services to pharmaceutical companies throughout the drug development lifecycle, from discovery to commercialization. The global oncology drug market is projected to reach $286.6 billion by 2031, presenting a significant opportunity for NeoGenomics to increase its revenue and market share. Timeline: Ongoing.
- Strategic Partnerships: Forming strategic partnerships with hospitals and research institutions can enhance NeoGenomics' market reach and access to patient samples. Collaborating with leading cancer centers can accelerate the adoption of its testing services and strengthen its reputation in the oncology community. These partnerships can also facilitate the development of new diagnostic assays and expand the company's testing portfolio. Timeline: Ongoing.
- Geographic Expansion: Expanding its presence in international markets, particularly in Asia and Europe, can drive growth for NeoGenomics. The increasing prevalence of cancer in these regions and the growing demand for advanced diagnostics create opportunities for the company to establish a stronger foothold. This expansion can be achieved through acquisitions, partnerships, or the establishment of new laboratories. Timeline: 2027-2030.
- Advancements in Molecular Testing: Investing in research and development to advance its molecular testing capabilities can provide NeoGenomics with a competitive edge. Developing new assays for detecting rare mutations and biomarkers can improve the accuracy and sensitivity of its diagnostic services. This can also enable the company to offer personalized medicine solutions tailored to individual patients. Timeline: Ongoing.
- Data Analytics and AI Integration: Integrating data analytics and artificial intelligence (AI) into its testing services can enhance the efficiency and accuracy of cancer diagnosis. AI-powered tools can analyze large datasets of genomic and clinical information to identify patterns and predict treatment outcomes. This can improve patient care and reduce healthcare costs. The global AI in healthcare market is projected to reach $95.7 billion by 2030. Timeline: 2028-2030.
Opportunities
- Expanding Pharma Services segment to capitalize on oncology drug development.
- Forming strategic partnerships with hospitals and research institutions.
- Geographic expansion into international markets.
- Advancements in molecular testing and personalized medicine.
Threats
- Intense competition from other diagnostic testing companies.
- Potential for reimbursement rate reductions from healthcare payers.
- Risk of intellectual property infringement.
- Economic downturn affecting healthcare spending.
Competitive Advantages
- Established network of cancer-focused testing laboratories.
- Comprehensive suite of testing services, including cytogenetics, molecular, and morphologic analysis.
- Strategic alliances with companies like Inivata Limited.
- Dual revenue streams from clinical and pharmaceutical services.
About NEO
Founded in 2001 and headquartered in Fort Myers, Florida, NeoGenomics, Inc. has established itself as a key player in the cancer diagnostics and testing industry. The company operates a network of laboratories across the United States, Europe, and Asia, offering a comprehensive suite of testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. NeoGenomics operates through two primary segments: Clinical Services and Pharma Services. The Clinical Services segment provides a range of diagnostic and prognostic testing services to aid in cancer detection, diagnosis, and treatment. The Pharma Services segment supports pharmaceutical companies in their oncology drug development programs, from discovery to commercialization. Its services include cytogenetics testing, fluorescence in-situ hybridization (FISH) testing, flow cytometry, immunohistochemistry, digital imaging, molecular testing, and morphologic analysis. These services assist in the study of chromosomes, DNA, RNA, and cellular proteins, providing critical insights for cancer research and treatment. NeoGenomics has a strategic alliance and laboratory services agreement with Inivata Limited, further expanding its capabilities and reach in the oncology testing market.
What They Do
- Operates a network of cancer-focused testing laboratories.
- Offers cytogenetics testing services to study chromosomes and diseases.
- Provides fluorescence in-situ hybridization (FISH) testing services to detect DNA sequences.
- Offers flow cytometry testing services to measure cell characteristics.
- Provides immunohistochemistry and digital imaging testing services to localize cellular proteins.
- Offers molecular testing services for DNA and RNA analysis.
- Provides morphologic analysis by pathologists for diagnosis.
- Supports pharmaceutical clients' oncology programs.
Business Model
- Generates revenue through clinical testing services for hospitals and oncologists.
- Provides pharma services to pharmaceutical companies for oncology drug development.
- Offers a range of diagnostic testing services, including cytogenetics, molecular, and morphologic analysis.
Industry Context
NeoGenomics, Inc. operates within the medical diagnostics and research industry, a sector experiencing growth driven by advancements in cancer research and personalized medicine. The market is competitive, with key players including ACRS (Arcturus Therapeutics Holdings Inc.), ARCT (Aclaris Therapeutics, Inc.), HUMA (Humacyte, Inc.), MDXH (MDxHealth SA), and QTRX (Quanterix Corporation). These companies offer various diagnostic and research solutions, creating a dynamic landscape. NeoGenomics differentiates itself through its comprehensive testing portfolio and its focus on both clinical and pharmaceutical services. The industry benefits from increasing demand for early cancer detection and targeted therapies, fueling growth opportunities for companies like NeoGenomics.
Key Customers
- Hospitals and reference laboratories.
- Pathologists and oncologists.
- Pharmaceutical firms.
- Researchers.
NEO Financials
NEO Price Today & Live Chart
NeoGenomics, Inc. (NEO) stock price: $7.55 (-0.21, -2.71%)
NEO Latest News
-
Earnings Scheduled For March 19, 2026
benzinga · Mar 19, 2026
-
Neo Performance Materials Reports Fourth Quarter 2025 Results
CNW Group · Mar 19, 2026
-
Earnings Scheduled For February 17, 2026
benzinga · Feb 17, 2026
-
NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro
Zacks · Feb 16, 2026
NEO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NEO.
Price Targets
Consensus target: $13.00
NEO MoonshotScore
What does this score mean?
The MoonshotScore rates NEO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Anthony Zook
CEO
Anthony Zook serves as the CEO of NeoGenomics, Inc., bringing extensive leadership experience in the healthcare and diagnostics industries. His career includes holding key executive positions at various healthcare companies, where he focused on driving growth, improving operational efficiency, and enhancing shareholder value. Zook's background encompasses strategic planning, business development, and financial management. He is responsible for overseeing NeoGenomics' strategic direction and operational performance.
Track Record: Under Anthony Zook's leadership, NeoGenomics has focused on expanding its testing capabilities and strengthening its partnerships with pharmaceutical companies. He has overseen strategic initiatives aimed at improving profitability and driving revenue growth. Zook has also emphasized innovation and the development of new diagnostic assays to enhance the company's competitive position in the oncology market. He manages 2200 employees.
NeoGenomics, Inc. ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. NeoGenomics, Inc., as an ADR, allows U.S. investors to invest in the company without the complexities of cross-border transactions. The ADR represents a specific number of NeoGenomics shares held by a U.S. depositary bank.
- Home Market Ticker: United States
- ADR Level: 2
- ADR Ratio: 1:1
NEO Healthcare Stock FAQ
What does NeoGenomics, Inc. do?
NeoGenomics, Inc. operates as a network of cancer-focused testing laboratories, providing a comprehensive suite of services to hospitals, pharmaceutical firms, and researchers. The company's offerings include cytogenetics, molecular, and morphologic analysis, aiding in cancer detection, diagnosis, and treatment. Through its Clinical Services and Pharma Services segments, NeoGenomics supports both clinical diagnostics and oncology drug development, positioning itself as a key player in the cancer diagnostics market. The company's strategic alliances and geographic presence further enhance its market position.
What do analysts say about NEO stock?
Analyst consensus on NeoGenomics, Inc. (NEO) reflects a mixed outlook, with considerations for both growth potential and financial challenges. Key valuation metrics, such as the negative P/E ratio, indicate current profitability concerns, while the gross margin suggests underlying earnings potential. Growth considerations include the company's ability to expand its Pharma Services segment and capitalize on advancements in molecular testing. Investors should monitor the company's financial performance and strategic initiatives to assess its long-term growth prospects. No buy or sell recommendations are made.
What are the main risks for NEO?
NeoGenomics, Inc. faces several risks, including intense competition from other diagnostic testing companies, potential reimbursement rate reductions from healthcare payers, and the risk of intellectual property infringement. Economic downturns could also affect healthcare spending, impacting the demand for its services. Regulatory changes in the healthcare industry pose an ongoing risk, requiring the company to adapt its operations and comply with evolving standards. These factors could affect NeoGenomics' financial performance and market position.
What are the key factors to evaluate for NEO?
NeoGenomics, Inc. (NEO) currently holds an AI score of 49/100, indicating low score. Analysts target $13.00 (+72% from $7.55). Key strength: Comprehensive range of cancer-focused testing services. Primary risk to monitor: Intense competition from other diagnostic testing companies. This is not financial advice.
How frequently does NEO data refresh on this page?
NEO prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NEO's recent stock price performance?
Recent price movement in NeoGenomics, Inc. (NEO) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $13.00 implies 72% upside from here. Notable catalyst: Comprehensive range of cancer-focused testing services. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider NEO overvalued or undervalued right now?
Determining whether NeoGenomics, Inc. (NEO) is overvalued or undervalued requires examining multiple metrics. Analysts target $13.00 (+72% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying NEO?
Before investing in NeoGenomics, Inc. (NEO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be outdated.
- Analyst ratings are subject to change.